NCT06472076 2025-09-10A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)GlaxoSmithKlinePhase 3 Active not recruiting88 enrolled